Pfizer (PFE) Tops Q1 EPS by 2c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PFIZER REPORTS FIRST-QUARTER 2017 RESULTS
May 2, 2017 6:45 AM EDTFirst-Quarter 2017 Revenues of $12.8 Billion, Reflecting 1% Operational Decline, Unfavorably Impacted by One Less U.S. Selling Day and Two Fewer International Selling Days Compared to the Prior-Year Quarter First-Quarter 2017 Reported Diluted EPS(1) of $0.51, Adjusted Diluted EPS(2) of $0.69 Reaffirmed 2017 Financial Guidance
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2017 and reaffirmed its 2017 financial guidance.
On June 24, 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (Anacor). Therefore, financial results for first-quarter 2017 reflect three months of legacy Anacor operations, which were immaterial.
On September 28, 2016, Pfizer... More
